5 Biotech Stocks to Buy for Blockbuster Potential

Akero Therapeutics

• Market value: $618.3 million
• TipRanks consensus price target: $31.25 (37% upside potential)
• TipRanks consensus rating: Strong Buy (opens in new tab)
• Akero Therapeutics (AKRO (opens in new tab), $22.86) is developing medicines to reverse the course of serious metabolic diseases. Right now, that means advancing the company’s lead program, AKR-001, to provide a powerful new therapy for patients with NASH (non-alcoholic steatohepatitis) – a fatty liver disease.

NASH is closely linked to the obesity and diabetes epidemics seen around the world. It is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, which can progress to cancer and even death. The National Institutes of Health says up to 12% of U.S. adults – or 30 million people – have this disease. Thus, NASH represents a lucrative blockbuster opportunity for pharmaceutical companies and biotech stocks.

A few analysts believe that even though lead asset AKR-001 is the new kid on the NASH block, the drug has a promising future.

Jefferies analyst Michael Yee is one of four analysts who initiated coverage of the stock following its late-June initial public offering (IPO). He started the stock at Buy, with a $28 price target (22% implied upside), citing “the potential for lead NASH drug AKR-001 to show strong data in (2020) that reflect blockbuster potential and best-in-class profile.”

The NASH space has been challenging for investors, but Yee believes Akero “represents a relatively cheap and semi-derisked NASH company.” It thinks the biotech stock will appreciate ahead of the release of Phase 2 data, anticipated in the first half of 2020, and that the data itself could lift the stock another 50% to 100%.

Yee is not alone. Evercore ISI’s Josh Schimmer calls Akero a “rising NASH star,” rating its stock a Buy with a Street-high $35 price target, suggesting 53% upside. JPMorgan’s Eric Joseph (Buy, $28) says AKR-001 has “best-in-class potential.” Get the full scoop on the analyst consensus at TipRanks (opens in new tab).

Dermira

• Market value: $448.1 million
• TipRanks consensus price target: $20.33 (143% upside potential)
• TipRanks consensus rating: Strong Buy (opens in new tab)
• Dermira (DERM (opens in new tab), $8.35) develops therapies meant to improve the lives of the millions of people living with chronic skin conditions This includes hyperhidrosis (excessive sweating) and atopic dermatitis (a widespread condition that leads to severe, persistent itching).

This is an interesting company in that its main drug isn’t a pill or a serum, but a medicated cloth. Qbrexa, Dermira’s only marketed product, is a topical treatment for excessive underarm sweating. However, it also has an injectable antibody – lebrikizumab, for atopic dermatitis – that has recently completed Phase 2 trials and is expected to enter Phase 3 testing by the end of 2019. Cantor Fitzgerald analyst Louise Chen thinks both treatments have blockbuster potential.

“The peak sales potential of Qbrexza for hyperhidrosis and lebrikizumab for AD are underappreciated, in our view,” cheers Chen, who has a $25 price target on DERM (199% upside potential) and is enthusiastic about the prospects for Qbrexa to treat sweaty hands – a condition that affects about 6 million Americans. “We think both Lebrikizumab and Qbrexza have peak sales potential of ($1 billion or more) each, which is not reflected in DERM’s valuation, in our opinion.” Over the past three months, Dermira has received three Buy ratings – and that swells to nine, versus just one Hold, over the past nine months.

“We also think DERM is an interesting company in a consolidating space. Therefore, we expect upward earnings revisions and multiple expansion to drive the stock higher,” Chen writes.

Check out more opinions from the pros at TipRanks (opens in new tab).

Global Blood Therapeutics

• Market value: $3.4 billion
• TipRanks consensus price target: $96 (71% upside potential)
• TipRanks consensus rating: Strong Buy (opens in new tab)
• Global Blood Therapeutics (GBT (opens in new tab), $57.22) is one of a few biotech stocks developing innovative treatments for rare blood diseases. Its lead candidate is voxelotor (GBT440), an oral, once-daily first-in-class breakthrough for the treatment of sickle cell disease (SCD).

Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. According to the National Library of Medicine, this is the most common inherited blood disorder in the U.S., affecting around 70,000 to 80,000 Americans.

We are heading toward a critical time for GBT. The company is planning to submit a New Drug Application (NDA) under accelerated approval by the end of the year.

Top William Blair analyst Raju Prasad recently attended the company’s upbeat investor event at the European Hematology Association’s annual meeting. “Given the effects across all subgroups in the study, the addressable market for the drug gives us confidence in its blockbuster potential,” he writes. He believes the strong Phase 3 HOPE trial data supports a likely approval for voxelotor in 2020, adding that, if approved, the drug should “become a mainstay of treatment.”

Wedbush analyst Liana Moussatos recently reiterated her Buy rating on GBT with a $103 price target (80% upside potential). She explains, “We project potential achievement of almost $1 billion in gross worldwide sales in 2023 after our estimated U.S. launch in August 2020 and peak worldwide sales of $5 billion in 2027.”

This Strong Buy biotech stock has received nine Buy ratings over the past three months, versus just one Hold. See why other top analysts are bullish on Global Blood Therapeutics (opens in new tab).

Moderna

• Market value: $4.8 billion
• TipRanks consensus price target: $29.71 (105% upside potential)
• TipRanks consensus rating: Strong Buy (opens in new tab)
• Moderna (MRNA (opens in new tab), $14.47) is pioneering a new approach to medicine. The company believes that messenger RNA (mRNA) can transform how medicines are discovered, developed and manufactured. Messenger RNA – sometimes dubbed “the software of life” – is the set of instructions by which cells make proteins and send them to various parts of the body. Moderna hopes to treat a broad spectrum of diseases that currently show limited treatment options.

Chardan Capital’s Gbola Amusa initiated coverage of MRNA in early June with a Buy rating and $40 price target (176% upside potential). He cited the potential for Moderna’s mRNA therapeutics platform to establish a new, disruptive class of medicines.

“Under a long-term blue skies scenario, mRNA technologies could in theory be used to express almost any protein in the body and therefore used to treat any disease,” Amusa writes. “We thus consider Moderna a core long-term holding for investors looking for exposure to the genomics revolution and the emergence of genetic medicines.”

Indeed, MRNA has quickly emerged with a 22-product pipeline in trial stages targeting interesting opportunities in everything from infectious diseases to immuno-oncology. Most recently, Moderna presented interim Phase 1 data for an mRNA personalized cancer vaccine, mRNA-4157 in solid tumors. “Moderna partnering on certain oncology indications reduces some cash burn, while 50-50 profit sharing, e.g. with Merck or AstraZeneca, maintains opportunities for upside should blockbuster opportunities progress to the market,” Amusa writes.

Among the seven analysts covering biotech stocks that have looked at Moderna over the past there months, all have rated it a Buy. What are the financial experts saying about MRNA’s outlook? Find out on TipRanks. (opens in new tab)

Morphic Holding

• Market value: $612.9 million
• TipRanks consensus price target: $29.33 (42% upside potential)
• TipRanks consensus rating: Strong Buy (opens in new tab)
• Morphic Holding (MORF (opens in new tab), $20.71), which was founded in 2014 by Harvard scientist-entrepreneur Tim Springer, represents an intriguing new investing opportunity. The company, which operates as Morphic Therapeutic, executed its initial public offering on June 27, pricing at $15 per share then opening at $18. The target has since floated up to near the $21 level.

Five-star Cowen analyst Ritu Baral believes Morphic is a stock with significant potential. She recently initiated MORF with a Buy rating, highlighting the company’s pipeline treatments for idiopathic pulmonary fibrosis (IPF, a type of chronic lung disease) and inflammatory bowel disease (IBD; e.g, Crohn’s disease and ulcerative colitis).

“We think MORF’s integrin chemistry platform (MInT) … has major potential to generate promising oral drug candidates with significant commercial potential” Baral writes. Morphic is developing its IPF drug with pharma giant AbbVie (ABBV (opens in new tab)), which could result in significant royalty revenues and rich milestone payments.

As for the IBD treatments, she writes that they “have potential as mono- or combotherapy options in UC and Crohn’s disease and could drive blockbuster sales.” Baral calls the company’s approach in IBD “strongly validated” given the success of Takeda Pharmaceutical’s (TAK (opens in new tab)) intravenous integrin offering Entyvio. Indeed, Jefferies’ Michael Yee describes Morphic’s MRβ7 compounds as an “oral Entyvio,” which he believes can conservatively be a $1 billion-to-$2 billion drug.

Four analysts initiated coverage of Morphic on July 22, all with Buy ratings. See why top analysts are bullish on Morphic (opens in new tab).

Harriet Lefton is head of content at TipRanks, a comprehensive investing tool that tracks more than 5,000 Wall Street analysts as well as hedge funds and insiders. You can find more of their stock insights here. (opens in new tab)